Pucotenlimab not checked
FollowEvery change as it happens, and a Monday email
Trials
4 active
4 in total · 1 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “MRG003 will be administrated as specified in the protocol. Pucotenlimab will be administrated as specified in the protocol.”In the company’s words, NCT06976190 on ClinicalTrials.gov
- Tested for
- Recurrent or Metastatic Nasopharyngeal Carcinoma, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma
- Main trialPhase 3
- “This is a randomized, open-label, multi-center, phase III study to evaluate the efficacy and safety, and immunogenicity of MRG003 in combination with pucotenlimab in patients with recurrent or metastatic nasopharyngeal carcinoma.”In the company’s words, NCT06976190 on ClinicalTrials.gov
Other drugs for Recurrent or Metastatic Nasopharyngeal Carcinoma
- DostarlimabGSK · Phase 3
- NiraparibGSK · Phase 3
- MezigdomideCelgene · Phase 3
- PlonmarlimabTJ Biopharma Co., Ltd. · Phase 3
- GumarontinibCSPC · Phase 2/3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
Coming up3
- Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- Apr 2028Phase 1/2 trial completes · ClinicalTrials.gov
- May 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | May 2029 | A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma | |
| Phase 2Recruiting | Dec 2027 | Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma | |
| Phase 1/2Recruiting | Apr 2028 | MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II) | |
| Phase 2Authorised | not given | Randomized Phase 2 trial of induction treatment of anti-PD-1 pucotenlimab and EGFR-ADC MRG003 or EGFR-ADC alone followed by chemoradiotherapy in locally advanced head and neck squamous cell carcinoma (LA-SCCHN). |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026